Radiopharmaceutical · Kills target cells, directed at leucine-rich repeat-containing protein 15 (LRRC15) · developed by Radiopharm Theranostics
Lutetium Lu 177-DOTA-DUNP19 LNTH2403 is a lutetium-177 radiolabeled, humanized IgG1 monoclonal antibody that binds the external domain of LRRC15, which is expressed on certain tumor and stromal cells. After binding and internalization, it delivers beta radiation to LRRC15-expressing cells and can be visualized by SPECT/CT. It is being studied in colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, and relapsed or refractory osteosarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07357519 | Phase 1/2 | Relapsed / Refractory Osteosarcoma | Recruiting | LNTH |
| NCT07272642 | Phase 1 | Imaging | Not yet recruiting | RADX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerHead and Neck Squamous Cell CarcinomaImagingNon-Small Cell Lung CancerRelapsed / Refractory OsteosarcomaTriple Negative Breast Cancer (TNBC)
Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.
See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RADX catalysts and pipeline →